Table 2.

Detailed description of the patients enrolled

PT	Age	Gender	Lesion localization based on US and/or CT imaging	Albendazole therapy duration (years)	Surgery (years before enrolment)	Whole‐blood IL‐4 test		Serology
						Indeterminate results	AgB results	HCF ELISA	EGP ELISA	AgB‐EITB	EM2PLUS ELISA	EM11 ELISA	EM18 ELISA
AE1	68	Female	Liver, myocardium, pericardium	2	2	No	Negative	Positive	Positive	NA	Positive	NA	Positive
AE2	68	Female	Liver	2	2	No	Negative	Negative	Negative	NA	Negative	NA	Negative
AE3	72	Male	Liver	4	‐	No	Negative	NA	NA	NA	Positive	Positive	NA
AE4	52	Male	Liver	1	‐	No	Negative	Positive	Positive	NA	Positive	NA	Positive
AE5	66	Male	Liver	2	5	No	Negative	Negative	Negative	NA	Negative	NA	NA
AE6	33	Male	Liver	8	7	Yes	Negative	NA	NA	NA	Positive	NA	NA
AE7	30	Female	Liver	0	‐	Yes	Negative	Positive	Positive	Positive	NA	Positive	NA
AE8	66	Female	Liver, abdominal wall	10a	‐	No	Negative	Positive	Positive	NA	NA	NA	Positive
AE9	76	Male	Liver, diaphragm, vena cava into right atrium	2b	‐	No	Negative	Positive	Positive	Positive	NA	Negative	Positive
AE10	82	Female	Liver	4	‐	No	Negative	NA	NA	Positive	Positive	NA	NA
AE11	65	Female	Liver	1	‐	No	Negative	Positive	Positive	NA	Positive	NA	NA
AE12	81	Male	Liver	1	‐	No	Negative	Positive	Positive	NA	Positive	NA	NA

Patient AE5 received albendazole for 2 years, and the treatment was discontinued 3 years before performing whole‐blood IL‐4 test; all other patients were receiving albendazole at the time of testing.

Abbreviations: AE, alveolar echinococcosis; AgB, antigen B; CT, computed tomography; HCF, hydatid cyst fluid; IL, Interleukin; NA, not available; PT, patient; US, ultrasound.

^aDays.

^bMonths.